McKesson Attracts Fresh Institutional Buying as Analysts Cluster Around $1,000 Price Targets

Institutional buyers add to McKesson stakes

Two institutional investors disclosed new positions in McKesson Corporation (NYSE: MCK) in filings referenced on September 10, 2026, adding to a broader pattern of portfolio managers increasing exposure to the drug distributor during the second quarter. South Korea's National Pension Service lifted its holding by 2.7% during the period, acquiring an additional 10,878 shares and bringing its stake to 407,092 shares worth roughly $307.6 million, equivalent to about 0.35% of the company. Separately, Scholtz & Company LLC established a new position of 6,473 shares valued at approximately $4.89 million, making McKesson about 2.4% of its portfolio and its 16th-largest holding. The two purchases were disclosed in separate recent regulatory filings.

The activity reflects continued institutional accumulation of McKesson shares. Institutional investors own 85.07% of the company, and several other asset managers have also reported recent changes to their McKesson positions in recent quarters.

Analyst targets converge near the $1,000 mark

Wall Street coverage of McKesson remains broadly positive, with 14 Buy ratings and four Hold ratings producing a "Moderate Buy" consensus and an average price target of $973.44. The cluster of targets has migrated higher in recent months: Citigroup raised its target to $1,000, TD Cowen set its target at $1,006, and Barclays lifted its objective from $925 to $1,000 with an Overweight rating on August 19, 2026. Weiss Ratings upgraded the shares from "buy (b-)" to "buy (b)" on September 4, 2026, while Evercore reissued an Outperform rating on August 6, 2026 and Morgan Stanley reaffirmed Overweight on August 7, 2026. Wall Street Zen moved in the opposite direction, cutting its rating from Buy to Hold on June 27, 2026.

McKesson shares opened at $894.38 on Thursday, September 10, 2026, up 0.6% on the session, with a 50-day moving average of $856.40 and a 200-day moving average of $841.46. The stock carries a market capitalization of $104.28 billion, a trailing P/E of 23.93, a P/E/G ratio of 1.77 and a beta of 0.30.

Quarterly results and FY 2027 outlook underpin sentiment

McKesson reported fiscal first-quarter results on August 5, 2026, posting adjusted earnings of $9.93 per share, ahead of the $9.56 consensus estimate by $0.37. Revenue of $105.38 billion rose 7.7% year over year and topped the $103.88 billion consensus. The company set FY 2027 guidance at $44.20 to $45.00 in adjusted EPS. The board also raised the quarterly dividend from $0.82 to $0.94, a move the filing data describes in annualized yield terms.

Other developments

Separately, McKesson announced on August 25, 2026 that it signed a definitive agreement to acquire Precision Medicine Group, LLC, a Bethesda, Maryland-based global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. Upon closing, Precision Medicine Group will sit within McKesson's Oncology & Multispecialty segment, which posted $14.2 billion in revenue in Q1 fiscal 2026. The transaction is subject to customary regulatory clearances.